-
Nxera unveils proprietary pipeline targeting obesity and metabolic disorders
06 Aug 2025 15:25 GMT
… chronic weight management
Nxera Pharma has launched a … management, co-morbid metabolic disorders and muscle preservation during … in developing potentially best-in-class next generation drug candidates … diseases, and expand treatment options for elderly and …
-
Y-mAbs signs off on $412M sale to SERB Pharmaceuticals, sending shares up 100%
06 Aug 2025 16:38 GMT
… treatment for relapsed or refractory high-risk neuroblastoma.
The drug won accelerated FDA … leader in developing better and … the global pharmaceutical company employs … drugs treat patients with certain cancers, neurologic syndromes and metabolic disorders …
-
Innovent Biologics receives US FDA clearance to initiate phase 1 clinical trial of novel oral GLP-1R agonist, IBI3032
06 Aug 2025 14:57 GMT
… US Food and Drug Administration (FDA) has approved the … possess potential in treating related diseases such … supporting the treatment of insulin-related metabolic diseases such as … . The company discovers, develops, manufactures and commercializes innovative …
-
Chemical Created by Brain Cells Could Unlock Next-Generation Weight Loss Drugs
06 Aug 2025 11:50 GMT
… different brain target for treating obesity and diabetes, … research and drug development for brain conditions. GLP-1 drugs, for … also a professor of pharmacology and medicine at … for the treatment of obesity and cardio-metabolic disease from Syracuse …
-
Discovery could lead to weight loss drugs with fewer side effects
06 Aug 2025 11:26 GMT
… different brain target for treating obesity and diabetes, … research and drug development for brain conditions. GLP-1 drugs, for … also a professor of pharmacology and medicine at … for the treatment of obesity and cardio-metabolic disease from Syracuse …
-
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
06 Aug 2025 11:00 GMT
… Phase 3 trial: The trial will utilize coronary … developing to overcome the limitations of current LDL-lowering treatments … -based, leading international pharmaceutical and diagnostics company. … in populations with metabolic diseases where currently approved …
-
A Network Pharmacology-Based Investigation into the Mechanism of Quercetin Combined with Rosuvastatin in Delaying Diabetic Nephropathy via Inhibiting NRK-52E Cell Ferroptosis
06 Aug 2025 09:14 GMT
… is the most common metabolic disorder worldwide, with its incidence … Potential Targets of Drugs in Treating DN
The targets … pathogenesis and the development of effective treatment strategies.25, … BK. Prescription cholesterol-lowering medication use in adults aged …
-
New Agreement Brings Breakthrough Dyslipidemia Treatment to Saudi Arabia and MEA
06 Aug 2025 08:07 GMT
… 47; -- Jamjoom Pharma, a leading Saudi pharmaceutical organization committed to … to developing and commercializing innovative therapies for cardiovascular and metabolic diseases, today … modern, affordable lipid-lowering treatment, to support patients across …
-
Pediatric research: how to fix a clinical trial system built for adults
06 Aug 2025 06:15 GMT
… across physiological, developmental, psychological, and pharmacological factors. Consequently, … continued global interest in treating brain disorders, childhood … 29.1% for metabolic disorders and 27.7% for … efficacy of medication in a clinical trial requires …
-
Health Canada taking longer to approve generic drugs, data show
06 Aug 2025 06:07 GMT
… meeting with Health Canada’s Pharmaceutical Drugs Directorate on June 23, show … sticker price of brand-name medications.
The lower prices are available … drug for phenylketonuria, a rare inherited metabolic disorder. Another is the breast-cancer drug …